论文部分内容阅读
为分析小儿急性淋巴细胞白血病诱导化疗早期骨髓象与预后的关系,对108例初治小儿急性淋巴细胞白血病进行MIC分型并随访,于诱导化疗第8天行骨髓检查,以骨髓幼稚细胞≤0.20为A组,骨髓幼稚细胞>0.20为B组。结果:(1)A组生存率明显高于B组(分别为84.2％和18％,P<0.05)。(2)A组中临床高危型比例明显低于B组(分别为27％和66％,P<0.05)。(3)临床普危型的病例中A组复发率明显低于B组(分别为3.9％和46％,P<0.05)。对临床难以分型的小儿急性淋巴细胞白血病,诱导化疗第8天骨髓检查对高危型判断有重要价值。
In order to analyze the relationship between prognosis and early bone marrow biopsy in children with acute lymphoblastic leukemia, 108 patients with untreated pediatric acute lymphoblastic leukemia were genotyped and followed up. Bone marrow examination was performed on the 8th day after induction of chemotherapy. Bone marrow marrow cells ≤0.20 Group A, bone marrow blast cells> 0.20 for the B group. Results: (1) The survival rate of group A was significantly higher than that of group B (84.2% and 18% respectively, P <0.05). (2) The proportion of clinical high-risk type in group A was significantly lower than that in group B (27% and 66% respectively, P <0.05). (3) The relapse rate of group A was significantly lower than that of group B (3.9% and 46%, respectively, P <0.05) in cases of clinically critical type. It is of great value to judge the high-risk type on the 8th day after inducing chemotherapy in pediatric acute lymphoblastic leukemia, which is difficult to be typed in clinic.